Early termination of ISRCTN45828668, a phase 1/2 prospective, randomized study of Sulfasalazine for the treatment of progressing malignant gliomas in adults
Authors:
- Pierre A RobePRPierre A Robe
- Didier H MartinDMDidier H Martin
- Minh T Nguyen-KhacMNMinh T Nguyen-Khac
- Maria ArtesiMAMaria Artesi
- Manuel DeprezMDManuel Deprez
- Adelin AlbertAAAdelin Albert
- Sophie VanbelleSVSophie Vanbelle
- Stephane CalificeSCStephane Califice
- Markus BredelMBMarkus Bredel
- Vincent BoursVBVincent Bours
Open Access
- 19 October 2009
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 9 (1) , 372
Abstract
Sulfasalazine, a NF-kappaB and x(c)-cystine/glutamate antiport inhibitor, has demonstrated a strong antitumoral potential in preclinical models of malignant gliomas. As it presents an excellent safety profile, we initiated a phase 1/2 clinical study of this anti-inflammatory drug for the treatment of recurrent WHO grade 3 and 4 astrocytic gliomas in adults.Keywords
This publication has 35 references indexed in Scilit:
- Reversible Encephalopathy Due to SulfasalazineClinical Neuropharmacology, 2008
- Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in GliomaThe Journal of Molecular Diagnostics, 2008
- Drug Induced Intracranial Hypertension Associated With Sulphasalazine TreatmentHeadache: The Journal of Head and Face Pain, 2007
- Tumor Necrosis Factor-α–Induced Protein 3 As a Putative Regulator of Nuclear Factor-κB–Mediated Resistance to O6-Alkylating Agents in Human GlioblastomasJournal of Clinical Oncology, 2006
- GNOSIS: Guidelines for neuro-oncology: Standards for investigational studies—reporting of phase 1 and phase 2 clinical trialsNeuro-Oncology, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- In vitro and In vivo Activity of the Nuclear Factor-κB Inhibitor Sulfasalazine in Human GlioblastomasClinical Cancer Research, 2004
- The ATM protein is required for sustained activation of NF-κB following DNA damageOncogene, 1999
- Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides.Journal of Clinical Investigation, 1998
- SulfasalazineDrugs, 1995